Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MDM2 amp |
| Therapy | N/A |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MDM2 amp | Advanced Solid Tumor | no benefit | N/A | Clinical Study | Emerging | In a clinical study, 100% (5/5) of solid tumor patients harboring MDM2 amplification experienced disease progression within 2 months of anti-PD1/PD-L1 monotherapy, indicating a risk for hyperprogression on immunotherapy (PMID: 28351930). | 28351930 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28351930) | Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. | Full reference... |